Get the Stockscreener App
14.20
0.92%
0.13
After Hours:
14.16
-0.04
-0.28%
Elanco Animal Health Inc stock is traded at $14.20, with a volume of 6.89M.
It is up +0.92% in the last 24 hours and down -3.01% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
See More
Previous Close:
$14.07
Open:
$14.3
24h Volume:
6.89M
Relative Volume:
1.22
Market Cap:
$7.05B
Revenue:
$4.45B
Net Income/Loss:
$205.00M
P/E Ratio:
35.50
EPS:
0.4
Net Cash Flow:
$372.00M
1W Performance:
-1.32%
1M Performance:
-3.01%
6M Performance:
+18.04%
1Y Performance:
+19.83%
1-Day Range:
$13.97
$14.40
1-Week Range:
$13.39
$14.47
52-Week Range:
$8.02
$15.78
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
2500 INNOVATION WAY, GREENFIELD
Compare ELAN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
14.20 | 6.99B | 4.45B | 205.00M | 372.00M | 0.40 |
|
ZTS
Zoetis Inc
|
146.12 | 67.59B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.20 | 45.04B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.29 | 42.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.71 | 18.00B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
304.81 | 13.24B | 2.99B | 1.21B | 1.13B | 25.06 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-17-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jun-26-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-09-24 | Initiated | UBS | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Market Perform |
| Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
What To Expect From Elanco’s (ELAN) Q2 Earnings - TradingView
1 Top Dividend Growth Stock to Buy and Hold Forever - The Motley Fool
What catalysts could drive Elanco Animal Health Incorporated stock higher in 2025Build wealth steadily with proven investment techniques - Jammu Links News
How does Elanco Animal Health Incorporated generate profit in a changing economyBuild a diversified portfolio for stability - Jammu Links News
How many analysts rate Elanco Animal Health Incorporated as a “Buy”Identify breakout stocks before they peak - Jammu Links News
Will Elanco Animal Health Incorporated rebound enough to break evenSwing Trading Plan With Smart Signals in Review - metal.it
Why is Elanco Animal Health Incorporated stock attracting strong analyst attentionFree Stock Chart Pattern Guide - Jammu Links News
What institutional investors are buying Elanco Animal Health Incorporated stockMaximize your portfolio’s growth potential - Jammu Links News
What are Elanco Animal Health Incorporated company’s key revenue driversGet timely market insights for better trades - Jammu Links News
Animal Sedatives Market Is Going to Boom | Major Giants Zoetis, Elanco, Merck Animal Health, Ceva Santé Animale - openPR.com
How volatile is Elanco Animal Health Incorporated stock compared to the marketSwing Trade Report To Watch Now - jammulinksnews.com
Unexpected Trends Reshaping the Veterinary Oncology U.S. - openPR.com
Sector Rotation Brings Elanco Animal Health Incorporated Into FocusMulti-Bagger Potential Stock Forecast Tools Released - beatles.ru
Animal Growth Promoter Market Size and Share Forecast Outlook - openPR.com
Fish Vaccine Market Generated Opportunities, Future Scope - openPR.com
Elanco Animal Health Incorporated (NYSE:ELAN) Shares Bought by Victory Capital Management Inc. - MarketBeat
Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Allianz Asset Management GmbH Sells 317,192 Shares of Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
European Commission approves Zenrelia - DVM360
Wyckoff Accumulation Phase Possible in Elanco Animal Health IncorporatedEntry Points For Growing Stocks Identified by Models - metal.it
Dogs Vaccines Market to Witness Comprehensive Growth by 2032 | - openPR.com
What are the latest earnings results for Elanco Animal Health IncorporatedLightning-fast capital gains - jammulinksnews.com
Does Elanco Animal Health Incorporated stock perform well during market downturnsBreakthrough profit margins - jammulinksnews.com
Elanco Animal Health Incorporated Company’s Quarterly Earnings Growth: What the Numbers SayMinimized Risk Trading Plan - metal.it
Universal Beteiligungs und Servicegesellschaft mbH Invests $5.70 Million in Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Elanco Animal Health Incorporated (NYSE:ELAN) Shares Purchased by Envestnet Asset Management Inc. - MarketBeat
Equitable Trust Co. Purchases 24,129 Shares of Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Elanco Animal Health (NYSE:ELAN) Price Target Raised to $18.00 - MarketBeat
Elanco Animal Health Incorporated (NYSE:ELAN) Shares Bought by Private Management Group Inc. - MarketBeat
Why Elanco (ELAN) Stock Is Trading Up Today - Yahoo Finance
Elanco Animal Health Incorporated Stock Analysis and ForecastLightning-fast capital gains - PrintWeekIndia
What drives Elanco Animal Health Incorporated stock priceLightning-fast growth - PrintWeekIndia
Elanco Secures Approval of Zenrelia™ (ilunocitinib) in the European Union (EU), Launching Innovative Canine Dermatology Treatment for Itchy Dogs - The Malaysian Reserve
Elanco Secures Approval of Zenrelia™ (ilunocitinib) in the European Union (EU), Launching Innovative Canine Dermatology Treatment for Itchy Dogs | ELAN Stock News - GuruFocus
EU Approval Boosts Elanco (ELAN) with Zenrelia Milestone | ELAN Stock News - GuruFocus
What analysts say about Elanco Animal Health Incorporated stockDynamic portfolio growth - PrintWeekIndia
ELAN vs. USPH: Which Stock Is the Better Value Option? - Yahoo Finance
Aquatic Veterinary Market Set to Witness Significant Growth - openPR.com
Elanco Secures Major EU Victory: New Once-Daily Dog Dermatitis Drug Matches Market Leader in Clinical Trial - Stock Titan
Elanco Animal Health (ELAN): UBS Maintains Buy Rating, Raises Pr - GuruFocus
Autogenous Vaccine for Aquaculture Market Generated - openPR.com
ELANCO SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Elanco Animal Health Inc. (NYSE:ELAN) And Encourages Long-Term Investors to Contact the FirmELAN - ACCESS Newswire
Is Elanco Animal Health Incorporated a good long term investmentHigh-profit trading signals - jammulinksnews.com
Are Medical Stocks Lagging Encompass Health (EHC) This Year? - Yahoo Finance
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.64%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):